Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), executed a transaction involving 9,500 shares of the company's common stock on June 5, 2026. The transaction included the exercise of stock options and the subsequent sale of the acquired shares, resulting in a total sale value of approximately $5.2 million. These actions were conducted under a pre-arranged 10b5-1 trading plan adopted in November 2025. The sale follows recent corporate developments, including the publication of phase 3 study results for nebulized Tyvaso in idiopathic pulmonary fibrosis and the reporting of first-quarter financial results that fell short of analyst consensus expectations.
The June 5 transaction involved the exercise of 9,500 stock options at an exercise price of $146.03 per share. This exercise resulted in an acquisition value of $1,387,285. The shares were subsequently sold at prices ranging from $545.345 to $550.58 per share. Both the exercise of the options and the sale of the shares were executed as part of a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is set to continue until either 1,734,410 stock options are exercised (all expiring on March 15, 2027) or December 31, 2026, whichever comes first.
Following these transactions, Ms. Rothblatt directly holds 40,513 shares of United Therapeutics common stock. Additionally, she holds indirect ownership of 166 shares through her spouse, 324,443 shares through family trusts where she shares investment power, 249,108 shares through family trusts where her spouse is a trustee, 45,596 shares through family trusts where her spouse shares investment power, and 8,902 shares through family trusts where she serves as a trustee.
The stock has delivered a strong 68.76% return over the past year, though InvestingPro analysis suggests the shares are currently trading slightly above their Fair Value. The company maintains a market capitalization of $23.15 billion and boasts an impressive gross profit margin of 86.58%.
In other recent news, United Therapeutics Corporation announced that its TETON-1 phase 3 study of nebulized Tyvaso for idiopathic pulmonary fibrosis met its primary endpoint. The study results, published in the New England Journal of Medicine, showed that Tyvaso preserved lung function and significantly reduced the risk of clinical worsening events.
Additionally, United Therapeutics reported first-quarter revenue of $781.5 million, which fell short of the consensus estimate of $797.4 million. Tyvaso revenues were $457.5 million, also below the expected $478.6 million, and the company’s net income was $274.9 million, missing the forecasted $320.5 million.
In partnership news, United Therapeutics is collaborating with Varda Space Industries to explore microgravity-based pharmaceutical processing for treatments targeting rare pulmonary diseases. This collaboration will involve pharmaceutical processing aboard Varda’s orbital manufacturing platform, aiming to enhance the stability and delivery of therapeutic compounds.
On the analyst front, TD Cowen reiterated its Buy rating on United Therapeutics, setting a price target of $675.00, while BTIG maintained a Neutral rating following the company’s earnings miss. These recent developments highlight United Therapeutics’ ongoing efforts in drug development and market performance.